1. Medtech Insight
  2. >>Business
  3. >>R&D
  4. >>Clinical Trials

Starts & Stops: J&J Launches IDE Trial Of 90-Watt RF Ablation Catheter; Vectorious Starts Trial Of V-LAP HF Monitor

 
• By Reed Miller

Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by MedDeviceTracker. This edition covers trial announcements from Feb. 4 through Feb. 10, including from Johnson & Johnson, Relievant Medsystems, Vectorious, Leviticus, and Kaia Health.

• Source: shutterstock.com

[Editors Note: Starts & Stops is Medtech Insight’s regular review of important medical device trial announcements as tracked by Informa’s MedDeviceTracker. Click here to request a demonstration. For an archive of previous Starts & Stops and Results Recap, the regular updates of trial-results announcements, visit the Tracking Trials page.]

The first of a planned 185 patients has been treated in the Investigational Device Exemption trial of Biosense Webster’s QDot Micro radiofrequency (RF) ablation catheter at New York University’s...

More from Clinical Trials

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

More from R&D